- Home
- CMPS vs DCTH Comparison
CMPS vs DCTH Comparison
Compare CMPS & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPS
- DCTH
- Stock Information
- Founded
- CMPS 2020
- DCTH 1988
- Country
- CMPS United Kingdom
- DCTH United States
- Employees
- CMPS N/A
- DCTH N/A
- Industry
- CMPS Biotechnology: Pharmaceutical Preparations
- DCTH Medical/Dental Instruments
- Sector
- CMPS Health Care
- DCTH Health Care
- Exchange
- CMPS Nasdaq
- DCTH Nasdaq
- Market Cap
- CMPS 280.2M
- DCTH 352.0M
- IPO Year
- CMPS 2020
- DCTH N/A
- Fundamental
- Price
- CMPS $4.03
- DCTH $11.34
- Analyst Decision
- CMPS Strong Buy
- DCTH Strong Buy
- Analyst Count
- CMPS 6
- DCTH 4
- Target Price
- CMPS $33.60
- DCTH $21.50
- AVG Volume (30 Days)
- CMPS 666.3K
- DCTH 346.0K
- Earning Date
- CMPS 10-31-2024
- DCTH 11-08-2024
- Dividend Yield
- CMPS N/A
- DCTH N/A
- EPS Growth
- CMPS N/A
- DCTH N/A
- EPS
- CMPS N/A
- DCTH N/A
- Revenue
- CMPS N/A
- DCTH $22,644,000.00
- Revenue This Year
- CMPS N/A
- DCTH $1,605.13
- Revenue Next Year
- CMPS N/A
- DCTH $111.67
- P/E Ratio
- CMPS N/A
- DCTH N/A
- Revenue Growth
- CMPS N/A
- DCTH 945.91
- 52 Week Low
- CMPS $3.86
- DCTH $3.70
- 52 Week High
- CMPS $12.75
- DCTH $13.30
- Technical
- Relative Strength Index (RSI)
- CMPS 37.75
- DCTH 51.29
- Support Level
- CMPS $3.86
- DCTH $10.75
- Resistance Level
- CMPS $4.20
- DCTH $13.30
- Average True Range (ATR)
- CMPS 0.29
- DCTH 0.70
- MACD
- CMPS 0.00
- DCTH -0.12
- Stochastic Oscillator
- CMPS 16.59
- DCTH 23.13
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.